HERBERT CHEN, MD
Radiology at Highland Ave, Madison, WI

License number
Wisconsin 42302
Category
Radiology
Type
Surgery
Address
Address
600 Highland Ave, Madison, WI 53792
Phone
(608) 263-7502
(608) 265-5530 (Fax)
(608) 829-5485

Organization information

See more information about HERBERT CHEN at bizstanding.com

Herbert Chen MD

600 Highland Ave, Madison, WI 53792

Industry:
Surgeons
Phone:
(608) 263-7502 (Phone)
Herbert Chen


General Surgery Clinics - Herbert Chen MD

600 Highland Ave #F4, Madison, WI 53792

Categories:
General Surgeons, Oncology Physicians & Surgeons, Physicians & Surgeons
Phone:
(608) 263-7502 (Phone)

Professional information

Herbert Chen Photo 1

Dr. Herbert Chen, Madison WI - MD (Doctor of Medicine)

Specialties:
General Surgery
Address:
U of Wisconsin Hospital and Clinics
600 Highland Ave, Madison 53792
(608) 263-6400 (Phone)
University Wscnsn Hlth Sgy Clin
600 Highland Ave #STE F4/210, Madison 53792
(608) 263-7502 (Phone)
Procedures:
Adrenalectomy, Intestinal Transplant (incl. Enterectomy), Lymph Node Biopsy or Excision, Open Thymectomy, Parathyroidectomy, Thyroidectomy or Thyroid Lobectomy
Conditions:
Adrenal Gland Cancer, Breast Cancer, Hyperparathyroidism, Intestinal Obstruction, Lung Cancer, Parathyroid (Gland) Cancer, Parathyroid (Gland) Disease, Parathyroid (Gland) Tumor: Other than Malignant, Secondary Malignancies, Thyroid Cancer
Certifications:
General Surgery, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Duke Univ Sch Of Med
Graduated: 1992
Johns Hopkins Hospital
Graduated: 1998
Graduated: 2000


Herbert Chen Photo 2

Compositions And Methods For Treating Neuroendocrine Tumors

US Patent:
2006012, Jun 8, 2006
Filed:
Dec 8, 2005
Appl. No.:
11/296404
Inventors:
Muthusamy Kunnimalaiyaan - Madison WI, US
Herbert Chen - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61K 48/00, A61K 39/395, A61K 31/5513, A61K 31/407, A61K 31/381
US Classification:
424146100, 514044000, 514221000, 514410000, 514438000
Abstract:
Methods and pharmaceutical compostions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising inhibiting the activities of GSK-3β of the cancer cells. Also disclosed are pharmaceutical compositions for the methods. Preferably, the pharmaceutical composition comprises Li+, SB216763, SB415286, indirubins, Paullones, Hymenialdisine, Azakenpaullone, Thienyl and phenyl α-halomethyl ketones, CHR 99021, AR-A014418, Bis-7-azaindolylmaleimides, CHR 98023, CHR-98014, and ZM336372, or a pharmaceutically acceptable salt or derivative thereof.


Herbert Chen Photo 3

Modulating Notch1 Signaling Pathway For Treating Neuroendocrine Tumors

US Patent:
8338482, Dec 25, 2012
Filed:
Jul 20, 2007
Appl. No.:
11/781142
Inventors:
Herbert Chen - Madison WI, US
Muthusamy Kunnimalaiyaan - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61K 31/19, C07C 53/128
US Classification:
514557, 562400
Abstract:
Methods and pharmaceutical compositions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising increasing the levels or activities of Notch1 protein or other components of the Notch1 signaling pathway of the cancer cells. Also disclosed are pharmaceutical compositions for the methods.


Herbert Chen Photo 4

Herbert Chen, Madison WI

Specialties:
Surgery, Surgical Oncology
Work:
University of Wisconsin at Madison
600 Highland Ave, Madison, WI 53792
Education:
Duke University(1992)


Herbert Chen Photo 5

Herbert Chen, Madison WI

Specialties:
Surgeon
Address:
600 Highland Ave, Madison, WI 53792
Board certifications:
American Board of Surgery Certification in Surgery


Herbert Chen Photo 6

Hydroxybenazamide Compounds For Treatment Of Cancer

US Patent:
2006002, Feb 2, 2006
Filed:
Jun 29, 2005
Appl. No.:
11/169512
Inventors:
Kyle Holen - Madison WI, US
Herbert Chen - Madison WI, US
Jamie Van Gompel - Kimberly WI, US
International Classification:
A61K 31/165
US Classification:
514616000
Abstract:
The present invention provides for the treatment of cancers, particularly neuroendocrine cancers, using the Raf-1 inducer ZM336372, or analogs thereof.